SCHEMBL15214785

SCHEMBL15214785

O=c1nc2c3ncn(Cc4ccccc4NO)c3ncnc-2n1Cc1cccc(NO)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 4/20 0.37
▸ PDE4A P27815 3/20 0.36
▸ PDE4B Q07343 3/20 0.36
▸ PDE4C Q08493 3/20 0.36
▸ PDE4D Q08499 3/20 0.36
▸ PDE5A O76074 2/20 0.36
▸ PDE1A P54750 2/20 0.36
▸ PDE1B Q01064 2/20 0.36
▸ PDE3B Q13370 2/20 0.36
▸ PDE1C Q14123 2/20 0.36
▸ PDE3A Q14432 2/20 0.36
▸ FGFR1 P11362 2/20 0.36
▸ FGFR4 P22455 2/20 0.36
▸ HTT P42858 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ PI4KA P42356 1/20 0.35
▸ PI4K2B Q8TCG2 1/20 0.35
▸ PI4K2A Q9BTU6 1/20 0.35
▸ PI4KB Q9UBF8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12112243 0.91 PIK3CD (0.40) PIK3CDPDE4APDE4BPDE4CPDE4D
SCHEMBL13394072 0.90 ADORA2A (0.41) PIK3CDADORA2API4KAPI4K2BPI4K2A
SCHEMBL15214783 0.88 PDE4A (0.41) PIK3CDPDE4APDE4BPDE4CPDE4D
SCHEMBL12112237 0.83 PDE4A (0.42) PIK3CDPDE4APDE4BPDE4CPDE4D
SCHEMBL13394063 0.82 PIK3CD (0.41) PIK3CDPDE4APDE4BPDE4CPDE4D
SCHEMBL12112229 0.81 SLC29A1 (0.43) PIK3CDPDE4APDE4BPDE4CPDE4D
SCHEMBL15214762 0.80 FGFR1 (0.47) PDE4APDE4BPDE4CPDE4DFGFR1
SCHEMBL12112236 0.80 PIK3CD (0.47) PIK3CDADORA2A
SCHEMBL12112232 0.79 PIK3CD (0.39) PIK3CDADORA2API4KAPI4K2BPI4K2A
SCHEMBL12112250 0.79 PIK3CD (0.37) PIK3CDADORA2API4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160319366-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO THE JOHNS HOPKINS UNIVERSITY (US) 2016-11-03 — — US disclosed
US-20160319366-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO THE JOHNS HOPKINS UNIVERSITY (US) 2016-11-03 — — US disclosed
US-9322831-B2 DDX3 as a biomarker for cancer and methods related thereto THE JOHNS HOPKINS UNIVERSITY (US) 2016-04-26 — — US disclosed
WO-2014149084-A2 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO THE JOHNS HOPKINS UNIVERSITY (US) 2014-09-25 — — WO disclosed
US-20130281440-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO THE JOHNS HOPKINS UNIVERSITY 2013-10-24 — — US disclosed
US-8518901-B2 Fused diimidazodiazepine compounds and methods of use and manufacture thereof THE JOHNS HOPKINS UNIVERSITY (US) 2013-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160319366-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO DDX3X, DDB1, DDX24 PIK3CD 2000/4885PDE4A 2061/4885PDE4B 2540/4885
US-20130281440-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO DDX3X, DDB1, DDX24 PIK3CD 2000/4885PDE4A 2061/4885PDE4B 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback